Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230.

@article{Kumarasamy2015LopinavirRitonavirMA,
  title={Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230.},
  author={Nagalingeshwaran Kumarasamy and Evgenia Aga and Heather Ribaudo and Carole Lorraine Wallis and David K. Katzenstein and Wendy S. Stevens and Michael R Norton and Karin L. Klingman and Mina C Hosseinipour and John A Crump and Khuanchai Supparatpinyo and Sharlaa Badal-Faesen and John A. Bartlett},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2015},
  volume={60 10},
  pages={1552-8}
}
BACKGROUND The AIDS Clinical Trials Group (ACTG) A5230 study evaluated lopinavir/ritonavir (LPV/r) monotherapy following virologic failure (VF) on first-line human immunodeficiency virus (HIV) regimens in Africa and Asia. METHODS Eligible subjects had received first-line regimens for at least 6 months and had plasma HIV-1 RNA levels 1000-200 000 copies/mL. All subjects received LPV/r 400/100 mg twice daily. VF was defined as failure to suppress to <400 copies/mL by week 24, or confirmed… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 6 times. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 13 references

Drug susceptibility and resistance mutations after first-line failure in resource limited settings.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2014

the Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial [abstract WELBB02

N Paton, C Kityo, A Hoppe, settings et al. A pragmatic randomised controlled strategy programme
7th International Conference on HIV Pathogenesis, Treatment and Prevention • 2013
View 2 Excerpts

High frequency of clinically significant mutations following first-line generic HAART failure: implications for second line options in resource-limited settings

N Kumarasamy, V Madhavan, K Venkatesh
Clin Infect Dis • 2009

Similar Papers

Loading similar papers…